Insulin resistance is concomitant with type 2 diabetes, obesity, hypertension, and other features of the metabolic syndrome. Because insulin resistance is associated with cardiovascular disease, both ...
Formally started in 1971 with the discovery of the insulin receptor, the field of insulin signalling has by now resolved many questions related to the cellular, biochemical foundation of the hormone's ...
The term 'insulin resistance' refers to a decrease in a target cell's metabolic response to insulin, or, at the whole-organism level, an impaired lowering effect of circulating or injected insulin on ...
Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...
Daily Express US on MSN
Diabetes breakthrough as century-old medicine 'helps manage type 1 diabetes'
A clinical trial found that metformin, a drug typically used for type 2 diabetes, reduced insulin requirements by around 12% ...
The findings have important implications, the authors wrote, as the study confirms “the potential clinical utility of empagliflozin for the treatment of obesity and related metabolic disorders, such ...
MENLO PARK, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (“CohBar” or the “Company”), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to ...
A cheap, century-old medication can improve life for people with type 1 diabetes, according to new research. A clinical trial ...
A budget-friendly 100-year-old medication could enhance life for people with type 1 diabetes, new research suggests. A ...
News-Medical.Net on MSN
Metformin fails to improve insulin resistance in type 1 diabetes
Metformin treatment in type 1 diabetes lowers insulin dosage but does not improve insulin resistance, highlighting its ...
A Garvan-led clinical trial has found that using a common and inexpensive type 2 diabetes drug reduces insulin needs in type ...
We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabetes and metabolic research,” said Mick Hitchcock, Ph.D., Interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback